Gyroscope secures $148M to develop treatment for rare eye diseases
Longevity Technology - 29-Mar-2021Funds to advance gene therapy for age-related macular degeneration & innovative delivery system
Join the club for FREE to access the whole archive and other member benefits.
Chief Executive Officer at Gyroscope
Khurem Farooq is Chief Executive Officer at Gyroscope. Prior to joining Gyroscope, Khurem served as the Senior Vice President of the Immunology and Ophthalmology business unit at Genentech, a member of the Roche Group. He began his career at Aventis in the United Kingdom holding various roles in sales and marketing.
Khurem holds a Master’s Degree in Business Administration as well as an Honours degree in Biological Sciences.
See also: Gyroscope Therapeutics - London-based company developing gene therapies and delivery technologies for eye diseases
Details last updated 31-Mar-2021
Funds to advance gene therapy for age-related macular degeneration & innovative delivery system